Literature DB >> 28447586

Serum vascular endothelial growth factor receptor-3 levels in patients with esophageal squamous cell cancer.

Aziz Su Mer, Ali Demir, Ahu Sarbay Kemik, Alpaslan Yavuz, Burak Suvak, Ahmet Cumhur Du Lger, Sevim Purisa, Ozgur Kemik.   

Abstract

AIM: Esophageal cancer is one of the most aggressive tumors of the gastrointestinal tract. In this study, we quantified the serum vascular endothelial growth factor-3 (VEGFR-3) expression in patients with esophageal squamous cell carcinoma (ESCC) to evaluate the role of VEGFR-3 in ESCC.
MATERIALS AND METHODS: Ninety five patients with ESCC were studied. Pre-therapy and preoperative samples were stored and ELISA was used to designate the concentrations of VEGFR-3.
RESULTS: The serum values of VEGFR-3 were significantly higher in patients with ESCC than in healthy donors (p<0.0001).
CONCLUSIONS: The results imply a very good sensitivity of VEGFR-3 in ESCC. VEGFR-3 may be a good diagnostic biomarker for ESCC. KEY WORDS: Biomarker, ESCC, VEGFR-3.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28447586

Source DB:  PubMed          Journal:  Ann Ital Chir        ISSN: 0003-469X            Impact factor:   0.766


  3 in total

1.  Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Lauren A King; Nicolas Wentzensen; Mark P Purdue; Hormuzd A Katki; Ligia A Pinto; Britton Trabert
Journal:  Ann Epidemiol       Date:  2021-12-11       Impact factor: 3.797

Review 2.  Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma.

Authors:  Manoj Kumar Kashyap; Omar Abdel-Rahman
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

3.  Co-expression of VEGF-C and survivin predicts poor prognosis in esophageal squamous cell carcinoma.

Authors:  Yun-Zhu Zeng; Yong-Qu Zhang; Xue-Qiong Lin; Jiong-Yu Chen; Fan Zhang; Jian-Ling Zhu; Xiao-Long Wei
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.